This workshop is hosted by the Sylvester Comprehensive Cancer Center’s Myeloma Research Institute, in collaboration with HealthTree Foundation for Multiple Myeloma, the Multiple Myeloma Research Foundation (MMRF) and the International Myeloma Foundation (IMF). VJHemOnc is pleased to be official media partner of the workshop.

This meeting will bring together leading experts in multiple myeloma to discuss the use of measurable residual disease (MRD) in clinical and trial settings, and will feature several opportunities for interactive discussion including a live fireside chat with an FDA representative.

Full agenda: https://www.vjhemonc.com/feature/miami-myeloma-mrd-meeting-2023/

Please apply for registration by filling in the form and confirming your details and then we will get back to you.

This meeting is supported by AbbVie, Adaptive, Amgen, CRISPR Therapeutics, GSK, Pfizer and Oncopeptides.